Salarius Pharmaceuticals Inc. Receives Nasdaq Extension and Announces Public Offering Plans

Salarius Pharmaceuticals Inc., a clinical-stage oncology company based in Houston, Texas, has recently made headlines with significant developments concerning its stock and compliance status. The company, which specializes in targeting the epigenetic causes of cancers, has been granted a conditional extension by the Nasdaq Stock Market LLC. This extension allows Salarius Pharmaceuticals additional time to regain compliance with the exchange’s continued listing requirements, specifically under Nasdaq Listing Rules 5550(a).

Stock Surge Following Public Offering Announcement

On June 17, 2025, Salarius Pharmaceuticals’ stock (SLRX) experienced a dramatic surge, increasing by 110% following the announcement of plans for a public offering of its shares. The company filed with the Securities and Exchange Commission (SEC) to outline these plans, although specific details such as the number of shares and their pricing were not disclosed. The filing did mention pre-funded warrants for investors whose stakes would exceed 4.99% due to the offering.

Market Reaction and Trading Volume

The announcement led to a significant increase in trading volume, with 26.6 million shares traded compared to a three-month daily average of approximately 36,000 units. Despite the substantial rally, SLRX stock was down 66.03% year-to-date as of Tuesday morning. The surge in stock price and trading volume highlights investor interest and market reaction to the company’s strategic moves.

Nasdaq Listing Extension

In addition to the public offering plans, Salarius Pharmaceuticals was granted a listing extension by the Nasdaq Hearings Panel. This extension provides the company with additional time to meet the exchange’s Equity Standard and Minimum Bid Price Requirement, ensuring continued compliance with Nasdaq’s listing standards.

Company Overview

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing treatments for cancer patients by targeting epigenetic causes. The company, which went public on January 29, 2015, is listed on the Nasdaq and serves residents of the State of Texas. With a market capitalization of $1,500,000 USD and a close price of $1.05 on June 16, 2025, the company has experienced significant fluctuations in its stock price, with a 52-week high of $7.2 and a low of $0.452.

Conclusion

The recent developments surrounding Salarius Pharmaceuticals Inc., including the Nasdaq extension and the announcement of a public offering, have significantly impacted the company’s stock performance and market perception. As the company continues to navigate its compliance requirements and strategic initiatives, investors and market watchers will closely monitor its progress and potential growth opportunities.